<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1301256586
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1998
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ANZATAX 6MG-ML VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PACLITAXEL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        6
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        concentrate for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        168.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="HOSPIRA AUSTRALIA " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            HOSPIRA AUSTRALIA 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Australia Pty LTD
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01CD01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine is used to treat:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ovarian cancer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breast cancer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non-small cell lung cancer (NSCLC).</p><p>&nbsp;</p><p>This medicine belongs to a group of medicines called antineoplastic or cytotoxic medicines. You may also hear of these being called chemotherapy medicines.</p><p>&nbsp;</p><p>It works by killing cancer cells and stopping cancer cells from growing and multiplying.</p><p>&nbsp;</p><p><strong>Ask your doctor if you have any questions about why this medicine has been prescribed for you.</strong></p><p>Your doctor may have prescribed it for another reason.</p><p>&nbsp;</p><p>This medicine is not addictive.</p><p>&nbsp;</p><p>This medicine is available only with a doctor&rsquo;s prescription.</p><p>&nbsp;</p><p>There is not enough information to recommend the use of this medicine for children.</p><p><strong>&nbsp;</strong></p><p><strong>When you must not be given it</strong></p><p><strong>&nbsp;</strong></p><p><strong>You must not be given ANZATAX if you have an allergy to:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any medicine containing paclitaxel or other medicines similar to paclitaxel called taxanes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any of the ingredients listed at the end of this leaflet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any medicines containing castor oil, such as cyclosporin injection or teniposide injection.</p><p>&nbsp;</p><p>Some of the symptoms of an allergic reaction may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;wheezing or difficulty breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;swelling of the face, lips, tongue or other parts of the body</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;rash, itching or hives on the skin</p><p>&nbsp;</p><p><strong>You must not be given this medicine if you have a very low white blood cell (WBC) count.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Tell your doctor if you have an infection or high temperature.</strong></p><p>Your doctor may decide to delay your treatment until the infection has gone.&nbsp; A mild illness, such as a cold, is not usually a reason to delay treatment.</p><p>&nbsp;</p><p><strong>You must not be given this medicine if you are pregnant or plan to become pregnant. </strong></p><p>Like most cytotoxic medicines ANZATAX is not recommended for use during pregnancy.&nbsp; If there is any need to consider this medicine during your pregnancy, your doctor will discuss with you the benefits and risks of using it.</p><p><strong>&nbsp;</strong></p><p><strong>Males: tell your doctor if your partner plans to become pregnant while you are being treated with this medicine or shortly after you have stopped treatment with it.</strong></p><p><strong>&nbsp;</strong></p><p>ANZATAX may cause birth defects if either the male or female is being treated with it at the time of conception.&nbsp; It is recommended that you use some kind of birth control while you are being treated with ANZATAX and for at least 12 weeks after you stop using it.&nbsp; Your doctor will discuss this with you.</p><p>&nbsp;</p><p><strong>Do not breast-feed while you are being treated with this medicine.</strong></p><p>The active ingredient in ANZATAX passes into breast milk and there is a possibility that your baby may be affected.</p><p>&nbsp;</p><p><strong>If you are not sure whether you should start taking &nbsp;this medicine, talk to your doctor.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Before you are given it</strong></p><p><strong>&nbsp;</strong></p><p><strong>Tell your doctor if you have allergies to any other medicines, foods, preservatives or dyes.</strong></p><p>&nbsp;</p><p><strong>Tell your doctor if you have or have had any of the following medical conditions:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any blood disorder with a reduced number of red blood cells, white blood cells, or platelets</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any disease of the nerves</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lowered immunity due to diseases such as HIV/AIDS</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lowered immunity due to&nbsp; treatment with medicines such as cyclosporin, or other medicines used to treat cancer (including radiation therapy).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Or had a previous serious reaction to a similar drug to ANZATAX (called taxanes)</p><p>&nbsp;</p><p>Tell your doctor if you are pregnant or plan to become pregnant or are breast-feeding.</p><p>Your doctor can discuss with you the risks and benefits involved.</p><p>&nbsp;</p><p><strong>If you have not told your doctor about any of these things, tell him/her before you start treatment with ANZATAX</strong>.</p><p><strong>&nbsp;</strong></p><p><strong>Taking other medicines</strong></p><p>&nbsp;</p><p><strong>Tell your doctor or pharmacist if you are taking any other medicines, including any that you get without a prescription from your pharmacy, supermarket or health food shop.</strong></p><p><strong>&nbsp;</strong></p><p>Some medicines and ANZATAX may interfere with each other.&nbsp; These include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cisplatin and doxorubicin, medicines used to treat cancer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; erythromycin, trimethoprim and rifampicin, antibiotics used to treat some bacterial infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gemfibrozil, a medicine used to lower high cholesterol levels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; deferasirox, a medicine used to treat iron overload</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; filgrastim, a medicine used for white blood cell disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fluoxetine, a medicine used to treat depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; carbamazepine, phenytoin and phenobarbital (phenobarbitone), medicines used for epilepsy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; efavirenz and nevirapine, medicines used to treat HIV (Human Immunodeficiency Virus) infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; herbal medicines containing St John&rsquo;s wort.</p><p>&nbsp;</p><p>These medicines may be affected by ANZATAX or may affect how well it works. You may need different amounts of your medicines, or you may need to take different medicines.</p><p>&nbsp;</p><p>Your doctor and pharmacist may have more information on medicines to be careful with or avoid while being treated with this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How much is given</strong></p><p>&nbsp;</p><p>Your doctor will decide what dose of ANZATAX you will receive.&nbsp; This depends on your condition and other factors, such as your weight, kidney function and other chemotherapy medicines you are being given.</p><p>&nbsp;</p><p><strong>Before you are given ANZATAX</strong>, <strong>you must take some other medicines to prevent allergic reactions occuring during your treatment. </strong></p><p><strong>&nbsp;</strong></p><p>You will need to take dexamethasone tablets 12 hours and 6 hours before your treatment, which your doctor will prescribe for you. You will also be given 2 different injections 30 to 60 minutes prior to receiving ANZATAX. This will minimize the risk of allergic reactions occuring.</p><p>&nbsp;</p><p>ANZATAX may be given alone or in combination with other drugs.</p><p>&nbsp;</p><p>Several courses of ANZATAX therapy may be needed depending on your response to treatment.</p><p>&nbsp;</p><p>Additional treatment may not be repeated until your blood cell numbers return to acceptable levels and any uncontrolled effects have been controlled.</p><p>&nbsp;</p><p><strong>Ask your doctor if you want to know more about the dose of ANZATAX you receive.</strong></p><p>&nbsp;</p><p><strong>How it is given</strong></p><p>&nbsp;</p><p>ANZATAX is usually given as an infusion (drip) into a vein over 3 hours.&nbsp;</p><p>&nbsp;</p><p><strong>How long it will be given for</strong></p><p>&nbsp;</p><p>ANZATAX is usually given once every three weeks. Each infusion is called one &lsquo;cycle&rsquo; of chemotherapy. Your doctor will decide how many of these cycles you will need.</p><p>&nbsp;</p><p><strong>If you receive too much (overdose)</strong></p><p>&nbsp;</p><p>As ANZATAX is given to you under the supervision of your doctor, it is very unlikely that you will receive too much.&nbsp; However, if you experience severe side effects after being given this medicine, tell your doctor or nurse immediately.</p><p>You may need urgent medical attention.</p><p>&nbsp;</p><p>Symptoms of an ANZATAX overdose include the side effects listed below in the &lsquo;Side Effects&rsquo; section, but are usually of a more severe nature.</p><p>&nbsp;</p><p><strong>If you experience severe side effects tell your doctor immediately, telephone your doctor or the Poisons Information Centre for advice, or go to Accident and Emergency at the nearest hospital, </strong></p><p>You may need urgent medical attention.</p><p>&nbsp;</p><p><strong>While you are being given ANZATAX Injection Concentrate</strong></p><p><strong>&nbsp;</strong></p><p>Things you must do</p><p>&nbsp;</p><p>If you are about to be started on any new medicine, remind your doctor and pharmacist that you are being treated with ANZATAX.</p><p><strong>&nbsp;</strong></p><p><strong>Tell any other doctors, dentists, and pharmacists who are treating you that you are being given this medicine.</strong></p><p><strong>If you are going to have surgery, tell the surgeon or anaesthetist that you are being treated with this medicine.</strong></p><p><strong>It may affect other medicines used during surgery.</strong></p><p>&nbsp;</p><p><strong>If you become pregnant while taking this medicine, tell your doctor immediately.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Keep all your doctor&rsquo;s appointments so your progress can be checked.</strong></p><p>Your doctor may want to check your blood pressure and do some blood and other tests from time to time to check on your progress and detect any unwanted side effects.</p><p>&nbsp;</p><p><strong>Keep follow-up appointments with your doctor.</strong></p><p>It is important to have your follow-up cycles of ANZATAX at the appropriate times to get the best effects from your treatments.</p><p>&nbsp;</p><p>This medicine can lower the number of white blood cells and platelets in your blood.&nbsp; This means that you have an increased chance of getting an infection or bleeding.&nbsp;</p><p>&nbsp;</p><p><strong>The following precautions should be taken to reduce your risk of infection or bleeding:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Avoid people who have infections.&nbsp; Check with your doctor immediately if you think you may be getting an infection, or if you get a fever, chills, cough, hoarse throat, lower back or side pain or find it painful or difficult to urinate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Be careful when using a toothbrush, toothpick or dental floss.&nbsp; Your doctor, dentist, nurse or pharmacist may recommend other ways to clean your teeth and gums.&nbsp; Check with your doctor before having any dental work.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Be careful not to cut yourself when you are using sharp objects such as a razor or nail cutters.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Avoid contact sports or other situations where you may bruise or get injured.</p><p>&nbsp;</p><p>Your body breaks down ANZATAX and uses it to fight cancer. The breakdown products may be excreted in body fluids and waste, including blood, urine, faeces, vomitus and semen.</p><p>&nbsp;</p><p><strong>In general, precautions to protect other people should be taken while you are receiving chemotherapy and for one week after the treatment period by:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flushing the toilet twice to dispose of any body fluids and waste.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wearing gloves to clean any spill of body fluid or waste.&nbsp; Use paper towels or old rags, a strong solution of non-bleaching detergent and large amounts of water to mop up the spill.&nbsp; Discard the towels or rags into a separate waste bag and dispose of fluids in the toilet.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wash linen or clothing that is heavily contaminated by body fluids or waste separately from other items.&nbsp; Use a strong solution of non-bleaching detergent and large amounts of water.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Place soiled disposable nappies and other pads in a plastic bag, seal and dispose into the garbage.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For sexual intercourse, use a barrier method such as a condom.</p><p><strong><em>&nbsp;</em></strong></p><p><strong>Things to be careful of</strong></p><p><strong>&nbsp;</strong></p><p><strong>Be careful driving or operating machinery until you know how ANZATAX affects you.</strong></p><p>This medicine may cause dizziness or light-headedness in some people. If you have these symptoms, do not drive, operate machinery or do anything else that could be dangerous.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How much is given</strong></p><p>&nbsp;</p><p>Your doctor will decide what dose of ANZATAX you will receive.&nbsp; This depends on your condition and other factors, such as your weight, kidney function and other chemotherapy medicines you are being given.</p><p>&nbsp;</p><p><strong>Before you are given ANZATAX</strong>, <strong>you must take some other medicines to prevent allergic reactions occuring during your treatment. </strong></p><p><strong>&nbsp;</strong></p><p>You will need to take dexamethasone tablets 12 hours and 6 hours before your treatment, which your doctor will prescribe for you. You will also be given 2 different injections 30 to 60 minutes prior to receiving ANZATAX. This will minimize the risk of allergic reactions occuring.</p><p>&nbsp;</p><p>ANZATAX may be given alone or in combination with other drugs.</p><p>&nbsp;</p><p>Several courses of ANZATAX therapy may be needed depending on your response to treatment.</p><p>&nbsp;</p><p>Additional treatment may not be repeated until your blood cell numbers return to acceptable levels and any uncontrolled effects have been controlled.</p><p>&nbsp;</p><p><strong>Ask your doctor if you want to know more about the dose of ANZATAX you receive.</strong></p><p>&nbsp;</p><p><strong>How it is given</strong></p><p>&nbsp;</p><p>ANZATAX is usually given as an infusion (drip) into a vein over 3 hours.&nbsp;</p><p>&nbsp;</p><p><strong>How long it will be given for</strong></p><p>&nbsp;</p><p>ANZATAX is usually given once every three weeks. Each infusion is called one &lsquo;cycle&rsquo; of chemotherapy. Your doctor will decide how many of these cycles you will need.</p><p>&nbsp;</p><p><strong>If you receive too much (overdose)</strong></p><p>&nbsp;</p><p>As ANZATAX is given to you under the supervision of your doctor, it is very unlikely that you will receive too much.&nbsp; However, if you experience severe side effects after being given this medicine, tell your doctor or nurse immediately.</p><p>You may need urgent medical attention.</p><p>&nbsp;</p><p>Symptoms of an ANZATAX overdose include the side effects listed below in the &lsquo;Side Effects&rsquo; section, but are usually of a more severe nature.</p><p>&nbsp;</p><p><strong>If you experience severe side effects tell your doctor immediately, telephone your doctor or the Poisons Information Centre for advice, or go to Accident and Emergency at the nearest hospital, </strong></p><p>You may need urgent medical attention.</p><p>&nbsp;</p><p><strong>While you are being given ANZATAX Injection Concentrate</strong></p><p><strong>&nbsp;</strong></p><p>Things you must do</p><p>&nbsp;</p><p>If you are about to be started on any new medicine, remind your doctor and pharmacist that you are being treated with ANZATAX.</p><p><strong>&nbsp;</strong></p><p><strong>Tell any other doctors, dentists, and pharmacists who are treating you that you are being given this medicine.</strong></p><p><strong>If you are going to have surgery, tell the surgeon or anaesthetist that you are being treated with this medicine.</strong></p><p><strong>It may affect other medicines used during surgery.</strong></p><p>&nbsp;</p><p><strong>If you become pregnant while taking this medicine, tell your doctor immediately.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Keep all your doctor&rsquo;s appointments so your progress can be checked.</strong></p><p>Your doctor may want to check your blood pressure and do some blood and other tests from time to time to check on your progress and detect any unwanted side effects.</p><p>&nbsp;</p><p><strong>Keep follow-up appointments with your doctor.</strong></p><p>It is important to have your follow-up cycles of ANZATAX at the appropriate times to get the best effects from your treatments.</p><p>&nbsp;</p><p>This medicine can lower the number of white blood cells and platelets in your blood.&nbsp; This means that you have an increased chance of getting an infection or bleeding.&nbsp;</p><p>&nbsp;</p><p><strong>The following precautions should be taken to reduce your risk of infection or bleeding:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Avoid people who have infections.&nbsp; Check with your doctor immediately if you think you may be getting an infection, or if you get a fever, chills, cough, hoarse throat, lower back or side pain or find it painful or difficult to urinate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Be careful when using a toothbrush, toothpick or dental floss.&nbsp; Your doctor, dentist, nurse or pharmacist may recommend other ways to clean your teeth and gums.&nbsp; Check with your doctor before having any dental work.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Be careful not to cut yourself when you are using sharp objects such as a razor or nail cutters.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Avoid contact sports or other situations where you may bruise or get injured.</p><p>&nbsp;</p><p>Your body breaks down ANZATAX and uses it to fight cancer. The breakdown products may be excreted in body fluids and waste, including blood, urine, faeces, vomitus and semen.</p><p>&nbsp;</p><p><strong>In general, precautions to protect other people should be taken while you are receiving chemotherapy and for one week after the treatment period by:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flushing the toilet twice to dispose of any body fluids and waste.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wearing gloves to clean any spill of body fluid or waste.&nbsp; Use paper towels or old rags, a strong solution of non-bleaching detergent and large amounts of water to mop up the spill.&nbsp; Discard the towels or rags into a separate waste bag and dispose of fluids in the toilet.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wash linen or clothing that is heavily contaminated by body fluids or waste separately from other items.&nbsp; Use a strong solution of non-bleaching detergent and large amounts of water.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Place soiled disposable nappies and other pads in a plastic bag, seal and dispose into the garbage.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For sexual intercourse, use a barrier method such as a condom.</p><p><strong><em>&nbsp;</em></strong></p><p><strong>Things to be careful of</strong></p><p><strong>&nbsp;</strong></p><p><strong>Be careful driving or operating machinery until you know how ANZATAX affects you.</strong></p><p>This medicine may cause dizziness or light-headedness in some people. If you have these symptoms, do not drive, operate machinery or do anything else that could be dangerous.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the reach and sight of children</p><p>&nbsp;</p><p>Store Below 25&ordm;C</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the vial label.&nbsp; The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>The published guidelines related to procedures for the proper handling and disposal of cytotoxic drugs should be followed.</p><p>&nbsp;</p><p>Care must be taken whenever handling cyostatic products.&nbsp; Always take steps to prevent exposure.&nbsp; This included appropriate equipment, such as wearing gloves and washing hands with soap and water after handling such products.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is Paclitaxel.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are anhydrous citric acid, castor oil and ethanol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Anzatax Injection Concentrate is a sterile solution containing 6 mg/mL paclitaxel, 2 mg/mL Anhydrous Citric Acid, 527 mg/mL Castor Oil and Ethanol.  It is a clear to pale yellow solution, free of visible particles.

Anzatax Injection Concentrate has a pH of 6 to 7.  Paclitaxel is extremely hydrophobic, and is therefore formulated in castor oil and ethanol.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>Pfizer Australia Pty Ltd, Level 17, 151 Clarence street, Sydney, NSW 2000,&nbsp;Australia<br /><strong>&nbsp;</strong></p><p><strong>Manufacturer:</strong></p><p><strong>&nbsp;</strong></p><p>HOSPIRA AUSTRALIA,</p><p>MULGRAVE,</p><p>Australia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                September 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يستخدم هذا الدواء في علاج التالي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان المبيض</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الثدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الرئة ذي الخلايا غير الصغيرة (NSCLC).</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينتمي هذا الدواء إلى مجموعة من الأدوية تسمى العوامل المضادة للأورام أو الأدوية السامة للخلايا. وقد تسمع تلك الأدوية يشار إليها أيضًا بمصطلح &quot;أدوية العلاج الكيميائي&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يعمل أنزاتاكس عن طريق قتل الخلايا السرطانية وإيقاف نموها وتكاثرها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اسأل طبيبك إذا كانت لديك أي أسئلة بشأن سبب وصف هذا الدواء لك.</p><p dir="RTL">قد يكون طبيبك قد وصفه لك لسبب آخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذا الدواء لا يسبب الإدمان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتم إتاحة هذا الدواء إلا بوصفة من الطبيب فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا توجد معلومات كافية للنصح باستخدام هذا الدواء في الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>موانع استعمال أنزاتاكس</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يجب ألا يتم إعطاؤك أنزاتاكس إذا كنت تعاني من حساسية تجاه:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي دواء يحتوي على باكليتاكسيل أو أدوية أخرى مشابهة لباكليتاكسيل تسمى تاكسانات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي من المكونات المذكورة في نهاية هذه النشرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي أدوية تحتوي على زيت الخروع، مثل حقن سيكلوسبورين أو حقن تينيبوسيد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن تتضمن بعض أعراض تفاعل الحساسية:</p><ul><li dir="RTL">ضيق التنفس</li><li dir="RTL">الأزيز أو صعوبة التنفس</li><li dir="RTL">تورم الوجه أو الشفتين أو اللسان أو أجزاء أخرى من الجسم</li><li dir="RTL">الطفح الجلدي أو الحكة أو ظهور الشرى على الجلد</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">يجب ألا يتم إعطاؤك هذا الدواء إذا كان تعداد خلايا الدم البيضاء (<strong>WBC</strong>) لديك منخفضًا للغاية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تعاني من عدوى أو ارتفاع في درجة الحرارة.</p><p dir="RTL">قد يقرر طبيبك تأخير علاجك حتى شفاء العدوى. لا يعتبر المرض الخفيف، مثل البرد، سببًا في تأخير العلاج عادة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يجب ألا يتم إعطاؤكِ هذا الدواء إذا كنتِ حاملًا أو تخططين للحمل.</p><p dir="RTL">كما هو الحال بالنسبة لمعظم الأدوية السامة للخلايا، يُوصى بعدم استخدام أنزاتاكس أثناء الحمل. إذا كانت هناك أي حاجة للنظر في استخدام هذا الدواء أثناء حملكِ، فسوف يناقش طبيبك الفوائد والمخاطر المترتبة على استخدامه معك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الذكور: أخبر طبيبك إذا كانت زوجتك تخطط للحمل أثناء خضوعك للعلاج باستخدام هذا الدواء أو بعد إيقافك العلاج بفترة قصيرة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">قد يسبب أنزاتاكس عيوبًا ولادية إذا كان الذكر أو الأنثى يخضعان للعلاج باستخدامه في وقت حدوث الحمل. يوصى باستخدام إحدى وسائل منع الحمل أثناء خضوعك للعلاج باستخدام أنزاتاكس ولمدة 12 أسبوعًا على الأقل بعد أن تتوقف عن استخدامه. سيناقش طبيبك هذا الأمر معك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تُرضعي رضاعة طبيعية أثناء خضوعكِ للعلاج باستخدام هذا الدواء.</strong></p><p dir="RTL">يمر المكون الفعال في أنزاتاكس إلى لبن الثدي ويحتمل أن يؤثر ذلك على طفلكِ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تكوني متأكدة مما إذا كان ينبغي البدء في أخذ هذا الدواء أم لا، فتحدثي إلى طبيبكِ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الاحتياطات عند استعمال أنزاتاكس</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أبلغ طبيبك إذا كنت تعاني من حساسية تجاه أي أدوية أخرى أو تجاه أي أطعمة أو مواد حافظة أو صبغات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أبلغ طبيبك إذا كنت تعاني أو سبق لك أن عانيت من أي من الحالات الطبية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض كلوي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو مرض كبدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو مشكلات في القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو أي اضطراب في الدم يكون مصحوبًا بانخفاض عدد خلايا الدم الحمراء أو خلايا الدم البيضاء أو الصفيحات الدموية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو أي مرض في الأعصاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو انخفاض المناعة نتيجةً للإصابة بأمراض مثل فيروس نقص المناعة البشرية (HIV)/الإيدز</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو انخفاض المناعة نتيجةً للعلاج باستخدام أدوية مثل سيكلوسبورين، أو الأدوية الأخرى التي تستخدم لعلاج السرطان (بما في ذلك العلاج الإشعاعي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو أُصبت من قبل بتفاعل خطير تجاه عقار مشابه لأنزاتاكس (يسمى تاكسانات)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبري طبيبكِ إذا كنتِ حاملًا أو تخططين لأن تصبحي حاملًا أو كنتِ تُرضعين رضاعة طبيعية.</strong></p><p dir="RTL">يمكن لطبيبكِ أن يناقش معكِ المخاطر والفوائد التي ينطوي عليها استخدامه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تكن قد أخبرت طبيبك بأي من هذه الأمور، فأخبره قبل أن تبدأ في العلاج باستخدام أنزاتاكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أي أدوية أخرى، بما في ذلك الأدوية التي تحصل عليها بدون وصفة طبية من الصيدلية أو السوبر ماركت أو متجر الأطعمة الصحية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تتداخل بعض الأدوية وأنزاتاكس مع بعضها البعض. وهذه الأدوية تتضمن:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيسبلاتين ودوكسوروبيسين، دوائين يستخدمان لعلاج السرطان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إريثروميسين، وتريميثوبريم، وريفامبيسين، مضادات حيوية تستخدم لعلاج بعض أنواع العدوى البكتيرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جيمفيبروزيل، دواء يستخدم لخفض مستويات الكولستيرول المرتفعة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديفيراسيروكس، دواء يستخدم لعلاج التحميل المفرط للحديد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيلجراستيم، دواء يستخدم لعلاج اضطرابات خلايا الدم البيضاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فلوكسيتين، دواء يستخدم لعلاج الاكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاربامازيبين، وفينيتوين، وفينوباربيتال (فينوباربيتون)، أدوية تستخدم لعلاج الصرع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيفافيرينز ونيفيرابين، دواءان يستخدمان لعلاج عدوى فيروس نقص المناعة البشرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية العشبية التي تحتوي على نبتة سانت جون</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تتأثر هذه الأدوية بأنزاتاكس أو قد تؤثر الأدوية على مدى كفاءة عمل أنزاتاكس. قد تحتاج إلى كميات مختلفة من أدويتك، أو قد تحتاج إلى تناول أدوية مختلفة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يكون لدى طبيبك والصيدلي المزيد من المعلومات حول الأدوية التي ينبغي توخي الحذر عند استخدامها أو تجنب استخدامها أثناء الخضوع للعلاج باستخدام هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الكمية التي يتم إعطاؤها</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقرر طبيبك ما هي الجرعة التي ستتلقاها من أنزاتاكس. ويعتمد هذا على حالتك وعلى عوامل أخرى، مثل وزنك وكفاءة وظائف الكلى لديك وأدوية العلاج الكيميائي الأخرى التي يتم إعطاؤها لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل أن يتم إعطاؤك أنزاتاكس،يجب أن تتناول بعض الأدوية الأخرى لمنع حدوث تفاعلات حساسية أثناء خضوعك للعلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف تحتاج إلى تناول أقراص ديكساميثازون قبل علاجك بـ12 ساعة و6 ساعات، والتي سيصفها لك طبيبك. وسيتم أيضًا إعطاؤك حقنتين مختلفتين قبل تلقي أنزاتاكس 30 إلى 60 دقيقة. سوف يقلل هذا من خطر حدوث تفاعلات الحساسية إلى الحد الأدنى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن إعطاء أنزاتاكس بمفرده أو بالتزامن مع عقاقير أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تكون هناك حاجة إلى تلقي عدة دورات من العلاج باستخدام أنزاتاكس بناءً على استجابتك للعلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا يتم تكرار العلاج الإضافي إلى أن يعود تعداد خلايا دمك إلى مستويات مقبولة وتتم السيطرة على أي آثار كانت خارجة عن السيطرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اسأل طبيبك إذا كنت ترغب في معرفة المزيد حول جرعة أنزاتاكس التي تتلقاها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كيف يتم إعطاء هذا الدواء</p><p dir="RTL">&nbsp;</p><p dir="RTL">عادة ما يعطى أنزاتاكس كتسريب (تنقيط) في وريد على مدار 3 ساعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ما هي المدة التي سيعطى خلالها</p><p dir="RTL">&nbsp;</p><p dir="RTL">عادة ما يعطى أنزاتاكس مرة واحدة كل 3 أسابيع. ويطلق على كل تسريب &quot;دورة&quot; واحدة من العلاج الكيميائي. سيقرر طبيبك العدد الذي ستحتاج إليه من هذه الدورات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من أنزاتاكس</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">نظرًا لأن أنزاتاكس يعطى لك تحت إشراف طبيبك، فمن المستبعد للغاية أن تتلقى جرعة أكبر من اللازم. ومع ذلك، إذا عانيت من آثار جانبية شديدة بعد إعطائك هذا الدواء، فأخبر طبيبك أو الممرضة على الفور.</p><p dir="RTL">قد تحتاج إلى عناية طبية عاجلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتضمن أعراض الجرعة المفرطة من أنزاتاكس الآثار الجانبية المذكورة أدناه بقسم &quot;الآثار الجانبية&quot;، ولكنها عادة ما تكون ذات طبيعة أكثر شدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبت بآثار جانبية شديدة فأخبر طبيبك على الفور، اتصل بطبيبك أو بمركز معلومات السموم لطلب الاستشارة أو اذهب إلى قسم الحوادث والطوارئ بأقرب مستشفى،</p><p dir="RTL">قد تحتاج إلى عناية طبية عاجلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أثناء إعطائك ركازة أنزاتاكس المخصصة للحقن</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأمور التي يجب عليك القيام بها</p><p>&nbsp;</p><p dir="RTL">إذا كنت على وشك بدء العلاج بأي دواء جديد، فقم بتذكير طبيبك والصيدلي أنك تخضع للعلاج باستخدام أنزاتاكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر أي أطباء وأطباء أسنان وصيادلة آخرين يقومون بعلاجك بأنه يتم إعطاؤك هذا الدواء.</p><p dir="RTL">إذا كنت ستخضع لعملية جراحية، فأخبر الجراح أو أخصائي التخدير بأنك تخضع للعلاج باستخدام هذا الدواء.</p><p dir="RTL">فقد يؤثر على الأدوية الأخرى المستخدمة أثناء الجراحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبحتِ حاملًا أثناء أخذ هذا الدواء، فأخبري طبيبكِ فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">التزم بجميع مواعيدك مع الطبيب للتمكن من التحقق من تقدم حالتك.</p><p dir="RTL">قد يرغب طبيبك في فحص ضغط دمك وإجراء بعض فحوصات الدم وبعض الفحوصات الأخرى من وقت لآخر للتحقق من تقدم حالتك ولاكتشاف أي آثار غير مرغوب فيها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">التزم بمواعيد المتابعة مع طبيبك.</p><p dir="RTL">من المهم أن تتلقى دورات المتابعة من أنزاتاكس في الأوقات المناسبة لتحصل على أفضل تأثير من علاجك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن لهذا الدواء أن يقلل عدد خلايا الدم البيضاء والصفيحات الدموية في دمك. ويعني ذلك أنك ستكون أكثر عرضة للإصابة بعدوى أو بنزيف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي اتخاذ الاحتياطات التالية لتقليل خطر إصابتك بعدوى أو بنزيف:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجنب الأشخاص المصابين بعدوى. تحقق من طبيبك فورًا إذا كنت تظن أنك قد تكون في بداية إصابتك بعدوى أو إذا أصبت بحمى أو قشعريرة أو سعال أو بحة في الصوت أو بألم في أسفل الظهر أو بألم في جنبك أو إذا وجدت صعوبة أو شعرت بألم أثناء التبول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توخ الحذر عند استخدام فرشاة الأسنان أو خلة الأسنان أو خيط تنظيف الأسنان. قد يوصي طبيبك أو طبيب الأسنان الخاص بك أو الممرضة أو الصيدلي باستخدام طرق أخرى لتنظيف أسنانك ولثتك. تحقق من طبيبك قبل الخضوع لأي إجراء بالأسنان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احرص على عدم جرح نفسك عند استخدامك للأدوات الحادة مثل الموسى أو أدوات قص الأظافر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجنب الرياضات التي تتطلب الالتحام أو المواقف الأخرى التي قد تجعلك عرضة للكدمات أو الإصابات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحلل جسمك أنزاتاكس ويستخدمه لمحاربة السرطان. ويمكن أن تفرز نواتج التحلل في سوائل وفضلات الجسم، بما في ذلك الدم والبول والبراز والقيء والسائل المنوي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بشكل عام، ينبغي اتخاذ احتياطات لحماية الأشخاص الآخرين أثناء تلقيك العلاج الكيميائي ولمدة أسبوع بعد فترة العلاج وذلك بعمل التالي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دفق ماء المرحاض مرتين للتخلص من أي سوائل أو فضلات أخرجها الجسم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتداء قفازات لتنظيف أي انسكاب لسوائل أو فضلات الجسم. استخدم مناشف ورقية أو مماسح قديمة ومحلولًا قويًا من منظف غير مبيض وكميات كبيرة من الماء لمسح الانسكاب. ثم تخلص من المناشف أو المماسح بوضعها في كيس نفايات منفصل وتخلص من السوائل في المرحاض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند غسل البياضات أو الأقمشة شديدة التلوث بسوائل أو فضلات الجسم، افصلها عن الأشياء الأخرى. استخدم محلولًا قويًا من منظف غير مبيض وكميات كبيرة من الماء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وضع الحفاضات والحشيات المتسخة الأخرى المخصصة للاستعمال لمرة واحدة في كيس بلاستيكي وإحكام غلقه والتخلص منه بإلقائه في القمامة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند ممارسة الجنس، استخدم وسيلة حاجزة مثل الواقي الذكري.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأمور التي يجب توخي الحذر حيالها</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير أنزاتاكس على القيادة واستخدام الآلات</strong></p><p dir="RTL">توخ الحذر عند قيادة السيارات أو تشغيل الآلات إلى أن تعرف كيف يؤثر أنزاتاكس عليك. يمكن أن يتسبب هذا الدواء في الشعور بدوار أو بدوخة عند بعض الأشخاص. إذا عانيت من هذين العرضين، فلا تقم بقيادة السيارات أو بتشغيل الآلات أو بفعل أي شيء آخر قد يشكل خطورة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الممرضة أو الصيدلي في أقرب وقت ممكن إذا كنت تشعر أنك لست على ما يرام أثناء إعطائك أنزاتاكس.</p><p dir="RTL">كما هو الحال مع الأدوية الأخرى التي تعالج السرطان، قد يكون لأنزاتاكس آثار جانبية غير مرغوب فيها، وبعضها قد يكون خطيرًا. قد تحتاج إلى علاج طبي إذا ظهرت عليك بعض الآثار الجانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تجعل القوائم التالية للآثار الجانبية تثير قلقك. فقد لا تصاب بأيٍ منها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اطلب من طبيبك أو الصيدلي الإجابة عن أي أسئلة قد تكون لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا لاحظت أيًا من الأمور التالية وكانت تثير قلقك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالعضلات أو بالمفاصل في الذراعين والساقين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان وقيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب بسهولة أثناء ممارسة نشاط بدني</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر الهضم، أو حرقة المعدة، أو الإسهال، أو الإمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في الجلد أو في مظهر الأظافر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب أو تقرح الفم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتضمن القائمة أعلاه الآثار الجانبية الأكثر شيوعًا للدواء الذي تتلقاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الممرضة في أقرب وقت ممكن إذا لاحظت أيًا من التالي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم وتورم وتهيج واحمرار في موضع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة أو دوار (نتيجة لانخفاض ضغط الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع، وتشوش، ومشكلات في الذاكرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم لاسع، أو تنميل أو خدر في أصابع اليدين و/أو القدمين و/أو الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد، أو تيبسه، أو تشققه، أو تقشره</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكون ثفن سميك وبثور على راحتي اليدين وباطني القدمين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في المشي أو استخدام يديك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في الرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتضمن القائمة أعلاه الآثار الجانبية الخطيرة التي قد تتطلب العناية الطبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا حدث أي من التالي، فأخبر طبيبك أو الممرضة فورًا، أو إذا لم تكن بالمستشفى، فاذهب إلى قسم الحوادث والطوارئ بأقرب مستشفى لك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس أو أزيز أو صعوبة في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه أو الشفتين أو اللسان أو أجزاء أخرى من الجسم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أو حكة أو شرى على الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب أو ضعف شديد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات، إغماء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة أو بطء أو عدم انتظام ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفقان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد أو العينين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف أو تكدم غير معتاد (بما في ذلك وجود دم في البراز أو البول لديك)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى أو التهاب في الحلق أو غيرها من علامات الإصابة بعدوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتضمن القائمة أعلاه الآثار الجانبية الخطيرة للغاية. قد تحتاج إلى عناية طبية عاجلة أو إلى المكوث في المستشفى في حال حدوثها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الممرضة أو الصيدلي إذا لاحظت أي أمر يجعلك تشعر أنك لست على ما يرام.</p><p dir="RTL">قد تحدث أيضًا مع بعض الأشخاص آثار جانبية أخرى غير مدرجة أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تستغرق فوائد أنزاتاكس وآثاره الجانبية بعض الوقت لكي تظهر. ولهذا، فحتى بعد أن تنتهي فترة تلقيك للعلاج، ينبغي أن تخبر طبيبك فورًا إذا لاحظت أيًا من الآثار الجانبية المدرجة في هذا القسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي بشأنها. يتضمن ذلك أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي (NPC)</p><ul><li dir="RTL">فاكس: 00966112057662 &lrm;</li><li dir="RTL">&nbsp;للاتصال بالمركز الوطني للتيقظ والسلامة الدوائية على رقم الهاتف: 00966112038222 ، تحويلة: 2317-2356-2340.</li><li dir="RTL">مركز الاتصال: 19999</li><li dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</li><li dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa/&nbsp;&nbsp;</li></ul></td></tr></tbody></table><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:610px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة</em><em>.</em></p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن متناول ومرأى الأطفال</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 25 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على ملصق القارورة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي اتباع التوجيهات الصادرة بشأن الإجراءات الملائمة للتعامل مع العقاقير السامة للخلايا والتخلص منها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب إعمال الحذر في أي وقت يتم فيه التعامل مع المنتجات المثبطة لنمو الخلايا. قم دائمًا باتخاذ خطوات لمنع التعرض لهذه المنتجات. يتضمن هذا المعدات الملائمة، مثل ارتداء القفازات وغسل اليدين بالصابون والماء بعد التعامل مع مثل هذه المنتجات.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي باكليتاكسيل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي حمض الستريك اللا مائي وزيت الخروع وإيثانول.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ركازة أنزاتاكس المخصصة للحقن هي محلول معقم يحتوي على 6 مجم/مل باكليتاكسيل، و2 مجم/مل حمض ستريك لا مائي و527 مجم/مل زيت خروع وإيثانول. وهي محلول صافٍ لونه يميل إلى الأصفر الفاتح، وخالٍ من الجسيمات المرئية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتراوح مستوى حموضة ركازة أنزاتاكس المخصصة للحقن بين 6 و7. إن باكليتاكسيل هو مادة كارهة جدًا للماء، ولذلك يتم تركيبه في زيت خروع وإيثانول.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الشركة المسوقة</p><p>Pfizer Australia Pty Ltd, Level 17, 151 Clarence street, Sydney, NSW 2000,&nbsp;Australia</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">الشركة المصنعة:<strong> </strong></p><p dir="RTL">Hospira Australia, Mulgrave, Australia</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            سبتمبر/أيلول 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Anzatax Injection concentration 6mg/mL vial
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Paclitaxel is an anticancer agent from the taxane class of drugs.
Anzatax Injection Concentrate is a sterile solution containing 6 mg/mL paclitaxel.  It is a white powder.  Paclitaxel is extremely hydrophobic, and is therefore formulated in castor oil and ethanol.
Excipients with known effect:
Ethanol
For the full list of excipients, see section 6.1 List of excipients.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for injection.
Anzatax Injection Concentrate has a pH of 6 to 7.  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Anzatax Injection Concentrate is indicated for the primary treatment of ovarian cancer in combination with a platinum agent.</p><p>Anzatax Injection Concentrate is indicated for the treatment of metastatic ovarian cancer and metastatic breast cancer, after failure of standard therapy.</p><p>Anzatax Injection Concentrate is indicated for the treatment of non-small cell lung cancer (NSCLC).</p><p>Anzatax Injection Concentrate is indicated for adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide.</p><p>Anzatax Injection Concentrate is indicated for the treatment of metastatic cancer of the breast, in combination with trastuzumab (Herceptin), in patients who have tumours that over-express HER-2 and who have not received previous chemotherapy for their metastatic disease.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dosage</p><p>All patients should be premedicated before paclitaxel is administered to prevent severe hypersensitivity reactions (see section 4.4 Special warnings and precautions for use).&nbsp; Before every treatment cycle, patients should be premedicated with:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dexamethasone 20 mg orally 12 hours and 6 hours prior to starting the paclitaxel infusion.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; promethazine 25 mg to 50 mg intravenously or other suitable H<sub>1</sub>-antagonist, 30 minutes prior to starting the paclitaxel infusion.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cimetidine 300 mg or ranitidine 50 mg by intravenous infusion over 15 minutes, starting 30 minutes prior to the paclitaxel infusion.</p><p>For primary treatment of ovarian cancer, it is recommended that paclitaxel be used at a dose of:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 175 mg/m<sup>2</sup>, administered intravenously over 3 hours, followed by cisplatin 75 mg/m<sup>2</sup>.&nbsp; The infusion should be repeated every three weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 135 mg/m<sup>2</sup>, administered intravenously over 24 hours, followed by cisplatin 75 mg/m<sup>2</sup>.&nbsp; The infusion should be repeated every three weeks.</p><p>For the treatment of metastatic ovarian cancer or metastatic breast cancer, it is recommended that paclitaxel be used as a single agent at a dose of 175 mg/m<sup>2</sup>.&nbsp; Paclitaxel should be administered as an intravenous infusion over 3 hours.&nbsp; The infusion should be repeated every 3 weeks as tolerated.&nbsp; Patients have tolerated treatment with up to 9 cycles of paclitaxel therapy, but the optimal course of therapy remains to be established.</p><p>For primary or secondary treatment of NSCLC, the recommended dose of paclitaxel is 175 mg/m<sup>2</sup> administered intravenously over 3 hours with a 3 week interval between courses.</p><p>For node positive breast cancer, the recommended dose of paclitaxel is 175 mg/m<sup>2</sup> administered intravenously over 3 hours every 3 weeks for four courses following doxorubicin and cyclophosphamide combination therapy.</p><p>For over-expression of HER-2 breast cancer, paclitaxel 175 mg/m<sup>2</sup> administered intravenously over 3 hours with a 3 week interval between courses for six cycles.&nbsp; Herceptin 2 mg/kg administered intravenously once a week until progression of disease after an initial loading dose of 4 mg/kg body weight.</p><p>Method of administration</p><p><u>Dilution</u></p><p>Anzatax Injection Concentrate MUST BE DILUTED PRIOR TO INTRAVENOUS INFUSION.&nbsp; It should be diluted in 5% glucose or 0.9% sodium chloride intravenous infusion.</p><p>Dilution should be made to a final concentration of 0.3 to 1.2 mg/mL.</p><p>After the final dilution of Anzatax Injection Concentrate, the bottle should be swirled gently to disperse the paclitaxel.&nbsp; DO NOT SHAKE.</p><p>Avoid contact of paclitaxel solutions with plasticised polyvinyl chloride (PVC) equipment,<strong> </strong>infusion lines or devices used when preparing infusion solutions.&nbsp; Prepare and store diluted paclitaxel solutions in glass bottles or non-PVC infusion bags.&nbsp; These precautions are to avoid leaching of the plasticiser DEHP (di-[2-ethylhexyl] phthalate) from PVC infusion bags or sets.&nbsp; Paclitaxel solutions should be administered through polyethylene lined administration sets (e.g., Gemini 20 giving set), using an IMED pump.</p><p>Although solutions of paclitaxel for infusion prepared as outlined above are chemically stable for 3 days at room temperature (25&deg;C) and 14 days at 2&deg;C to 8&deg;C, it is recommended that the solution for infusion should be administered immediately after preparation as it does not contain an antimicrobial agent.&nbsp; The infusion should be completed within 24 hours of preparation of the solution and any residue discarded, according to the guidelines for the disposal of cytotoxic drugs (see section 6.6 Special precautions for disposal).&nbsp; Use in one patient on one occasion only.</p><p>Compounding centres which:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are licensed by the TGA to reconstitute and/or further dilute cytotoxic products; and</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have validated aseptic procedure and regular monitoring of aseptic technique may apply the following shelf lives when stored under the specified conditions:</p><p>Table 1:</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td rowspan="2" style="vertical-align:top"><p>Diluent</p></td><td colspan="2" style="vertical-align:top"><p>Stored Below 25&deg;C</p></td><td colspan="2" style="vertical-align:top"><p>Stored at 2&deg;C to 8&deg;C (Refrigerate.&nbsp; Do not freeze)</p></td></tr><tr><td style="vertical-align:top"><p>Non-PVC Infusion Bag</p></td><td style="vertical-align:top"><p>Glass Bottle</p></td><td style="vertical-align:top"><p>Non-PVC Infusion Bag</p></td><td style="vertical-align:top"><p>Glass Bottle</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>0.9% Sodium Chloride for Intravenous Infusion</p></td><td style="vertical-align:top"><p>7 days</p></td><td style="vertical-align:top"><p>3 days</p></td><td style="vertical-align:top"><p>28 days</p></td><td style="vertical-align:top"><p>14 days</p></td></tr><tr><td style="vertical-align:top"><p>5% Glucose for Intravenous Infusion</p></td><td style="vertical-align:top"><p>7 days</p></td><td style="vertical-align:top"><p>3 days</p></td><td style="vertical-align:top"><p>14 days</p></td><td style="vertical-align:top"><p>14 days</p></td></tr></tbody></table><p>Solutions prepared this way have been shown to be chemically stable for these periods.&nbsp; Administration should be completed within 24 hours of the start of the infusion and any residue discarded according to the guidelines for the disposal of cytotoxic drugs.&nbsp; Do not use paclitaxel if any precipitation forms or if the diluted solution appears cloudy.</p><p><u>Filtration</u></p><p>A microporous membrane of 0.22 microns or less in size is recommended as the in-line filter for all infusions of paclitaxel.&nbsp; The IMED 0.2 micron add on filter set composed of polysulfone and the IVEX&trade; II 0.2 micron filter composed of cellulose have both been found to be suitable for Anzatax Injection Concentrate.</p><p>Paclitaxel is a cytotoxic anticancer drug and as with other potentially toxic compounds, caution should be exercised in handling paclitaxel.&nbsp; The use of gloves is recommended.&nbsp; Following topical exposure, tingling, burning, redness have been observed.&nbsp; If paclitaxel solution contacts the skin, wash the skin immediately and thoroughly with soap and water.&nbsp; If paclitaxel contacts mucous membranes, the membranes should be flushed thoroughly with water.&nbsp; Upon inhalation, dyspnoea, chest pain, burning eyes sore throat and nausea have been reported.&nbsp; Given the possibility of extravasation, it is advisable to closely monitor the infusion site for possible infiltration during drug administration.</p><p>Dosage adjustment</p><p>Subsequent doses of paclitaxel should be administered according to individual patient tolerance. Repetition of a course of paclitaxel is not recommended until the patient&rsquo;s neutrophil count is at least 1.5 &times; 10<sup>9</sup> cells/L (1,500 cells/mm<sup>3</sup>) and the platelet count is at least 100 &times; 10<sup>9</sup> cells/L (100,000 cells/mm<sup>3</sup>).&nbsp; If there is severe neutropenia (neutrophil count less than 0.5 &times; 10<sup>9</sup> cells/L) or severe peripheral neuropathy or severe mucositis during paclitaxel therapy, the dose of paclitaxel in subsequent courses should be reduced by 20% (see section 4.4 Special warnings and precautions for use).&nbsp; The incidence of neurotoxicity and the severity of neutropenia increase with dose within a regime.</p><p>Hepatic impairment:</p><p>Inadequate data are available to recommend dosage alterations in patients with mild, moderate and severe hepatic impairments (see Section&nbsp;4.4 Special warnings and precautions for use).</p><p>Paediatric population:</p><p>Paclitaxel is not recommended for use in children below 18&nbsp;years due to lack of data on safety and efficacy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Anzatax Injection Concentrate must not be used in patients who have exhibited hypersensitivity reactions to paclitaxel or other taxanes.
Anzatax Injection Concentrate must not be used in patients who have a history of hypersensitivity reactions to castor oil or drugs formulated in castor oil (e.g., ciclosporin for injection concentrate and teniposide for injection concentrate) or any of the other excipients.
Anzatax Injection Concentrate should not be administered in patients with solid tumours who have a baseline neutrophil counts of < 1.5 × 109 cells/L.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General</p><p>Paclitaxel should be administered under the supervision of a physician experienced in the use of chemotherapeutic agents.&nbsp; Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available.</p><p>Paclitaxel should be given before a platinum compound when it is given in combination with a platinum compound.</p><p>Premedication</p><p>In order to minimise the possibility of hypersensitivity reactions due to histamine release, patients should be premedicated before every treatment cycle of paclitaxel.&nbsp; Premedication should include corticosteroids (e.g., dexamethasone), antihistamines (e.g., diphenhydramine or promethazine) and an H<sub>2</sub>-receptor antagonist (e.g., cimetidine or ranitidine) (see section 4.2 Dose and method of administration).&nbsp; The characteristic symptoms of hypersensitivity reactions are dyspnoea and hypotension both requiring treatment, angioedema and widespread urticaria.&nbsp; In clinical trials, 2% of patients treated with paclitaxel experienced severe hypersensitivity.&nbsp; One of these reactions was fatal in a patient treated without premedication.&nbsp; Anzatax&trade; Injection Concentrate must not be used in patients who have exhibited hypersensitivity reactions to paclitaxel.</p><p>Neutropenia (see section 4.8 Adverse effects (undesirable effects))</p><p>As the dose limiting toxicity of paclitaxel is dose related bone marrow suppression (primarily neutropenia), paclitaxel should not be administered to patients with a pre-treatment neutrophil count of less than 1.5 &times; 10<sup>9</sup> cells/L (1,500 cells/mm<sup>3</sup>) or platelet count of less than 100 &times; 10<sup>9</sup> cells/L.&nbsp; Blood counts should be frequently monitored during treatment with paclitaxel.&nbsp; Further cycles of paclitaxel should not be administered until the patient&rsquo;s neutrophil count is greater than 1.5 &times; 10<sup>9</sup> cells/L (1,500 cells/mm<sup>3</sup>) and the platelet count is greater than 100 &times; 10<sup>9</sup> cells/L (100,000 cells/mm<sup>3</sup>).</p><p>If there is severe neutropenia during a course of paclitaxel (i.e., neutrophil count less than 0.5 &times; 10<sup>9</sup> cells/L [500 cells/mm<sup>3</sup>]), the dose of paclitaxel in subsequent cycles should be reduced by 20%.&nbsp; Previous radiation therapy may induce more severe myelosuppression.&nbsp; There is little information available from such patients at doses above 135 mg/m<sup>2</sup>.</p><p>Cardiovascular Toxicity</p><p>Hypotension, hypertension and bradycardia have been observed during paclitaxel administration, but generally do not require treatment. &nbsp;Frequent monitoring of vital signs, particular during the first hours of paclitaxel infusion is recommended (see also section 4.8 Adverse effects undesirable effects)).</p><p>Electrocardiographic monitoring is recommended for patients with serious conduction abnormalities and should be commenced for patients who develop abnormal cardiovascular symptoms or signs during monitoring of vital signs.</p><p>Severe cardiac conduction abnormalities have been reported rarely during paclitaxel therapy.&nbsp; If patients develop significant conduction abnormalities during paclitaxel administration, appropriate therapy should be administered and continuous electrocardiographic monitoring should be commenced and performed during subsequent therapy with paclitaxel (see section 4.8 Adverse effects (undesirable effects).&nbsp; Severe cardiovascular events were observed more frequently in patients with NSCLC than breast or ovarian cancer.</p><p>When paclitaxel is used in combination with trastuzumab or doxorubicin for treatment of metastatic breast cancer, monitoring of cardiac function is recommended. When patients are candidates for treatment with paclitaxel in these combinations, they should undergo baseline cardiac assessment including history, physical examination, ECG, echocardiogram, and/or MUGA scan. Cardiac function should be further monitored during treatment (eg, every 3&nbsp;months). Monitoring may help to identify patients who develop cardiac dysfunction and treating physicians should carefully assess the cumulative dose (mg/m<sup>2</sup>) of anthracycline administered when making decisions regarding frequency of ventricular function assessment. When testing indicates deterioration in cardiac function, even asymptomatic, treating physicians should carefully assess the clinical benefits of further therapy against the potential for producing cardiac damage, including potentially irreversible damage. If further treatment is administered, monitoring of cardiac function should be more frequent (eg, every 1‑2&nbsp;cycles).</p><p>Anaphylaxis and Severe Hypersensitivity Reactions</p><p>Severe hypersensitivity (anaphylactoid reactions characterised by dyspnoea and hypotension requiring treatment, angioedema and generalised urticaria have occurred rarely in premedicated patients receiving paclitaxel.&nbsp; Rare fatal reactions have occurred in patients despite pre-treatment.&nbsp; Cross-hypersensitivity between ANZATAX and other taxane products has been reported and may include severe reactions such as anaphylaxis.&nbsp; Patients with a previous history of hypersensitivity to other taxanes should be closely monitored during initiation of ANZATAX therapy.</p><p>Since significant hypersensitivity reactions may occur, appropriate supportive equipment should be available. Patients receiving paclitaxel should be under continuous observation for at least the first 30 mins following the start of the infusion and frequently thereafter.&nbsp; In case of a severe hypersensitivity reaction, paclitaxel infusion should be discontinued immediately and appropriate treatment given as indicated for anaphylaxis.&nbsp; The patient should not be rechallenged with the drug.&nbsp; Minor hypersensitivity reactions such as flushing, skin reactions etc do not require interruption of therapy (see also section 4.8 Adverse effects undesirable effects).</p><p>Gastrointestinal</p><p>In patients receiving paclitaxel who complain of abdominal pain with other signs and symptoms, bowel perforation should be excluded.</p><p>Administration</p><p>Anzatax Injection Concentrate is administered by intravenous infusion only; it must not be administered by the intracerebral, intrapleural or intraperitoneal routes.&nbsp; Anzatax Injection Concentrate must be diluted before intravenous infusion.&nbsp; Prior to intravenous infusion of paclitaxel, it must be ensured that the indwelling catheter is in the correct position as extravasation, necrosis and/or thrombophlebitis may result with incorrect administration (see section 4.2 Dose and method of administration).</p><p>Patients receiving paclitaxel should be under continuous observation for at least the first 30 minutes following the start of the infusion and frequently thereafter.&nbsp; In case of a severe hypersensitivity reaction, paclitaxel infusion should be discontinued immediately and appropriate treatment given as indicated for anaphylaxis.&nbsp; The patient should not be rechallenged with the drug.&nbsp; Minor hypersensitivity reactions such as flushing, skin reactions, etc. do not require interruption of therapy (see also section 4.8 Adverse effects undesirable effects).</p><p>In some patients, temporary discontinuation of the infusion is sufficient to resolve the symptoms.&nbsp; Other patients may require therapy with bronchodilators, adrenaline, antihistamines and corticosteroids, either alone or in combination.</p><p>Injection site reaction</p><p>A specific treatment for extravasation reaction is unknown at this time.&nbsp; Given the possibility of extravasation, it is advisable to closely monitor the infusion site for possible infiltration during drug administration.</p><p>Nervous system</p><p>Patients with pre-existing neuropathy should be carefully monitored.&nbsp; Peripheral neuropathy is frequently reported in patients receiving paclitaxel and the severity is dose dependent.&nbsp; A 20% reduction in paclitaxel dose is recommended for patients who develop peripheral neuropathy during therapy (see<strong> </strong>section 4.8 Adverse effects undesirable effects).</p><p>In NSCLC patients, the administration of paclitaxel in combination with cisplatin resulted in a greater incidence of neurotoxicity than usually seen in patients receiving single agent paclitaxel.</p><p>Paclitaxel contains ethanol, 396 mg/mL; consideration should be given to possible CNS and other effects of alcohol.</p><p>Children may be more sensitive than adults to the effects of ethanol.</p><p>Interstitial pneumonia</p><p>Paclitaxel in combination with radiation of the lung, irrespective of their chronological order, may contribute to the development of interstitial pneumonia.</p><p>Pseudomembranous colitis</p><p>Pseudomembranous colitis has been reported in patients who have not been concomitantly treated with antibiotics. This reaction should be considered in the differential diagnosis of cases of severe or persistent diarrhoea occurring during or shortly after treatment with paclitaxel.</p><p>Mucositis</p><p>Severe mucositis has been reported which requires dose reduction (see Section&nbsp;4.2).</p><p>Ophthalmology</p><p>There have been reports of reduced visual acuity due to cystoid macular oedema (CMO) during treatment with paclitaxel as well as with other taxanes (see Section&nbsp;4.8). Patients with visual impairment during paclitaxel treatment should seek a prompt and complete ophthalmologic examination. Paclitaxel should be discontinued if a CMO diagnosis is confirmed.</p><p>Use in hepatic impairment</p><p>The effect of hepatic impairment on the pharmacokinetics of paclitaxel has not been established.&nbsp; However, as the liver is thought to be the primary site for metabolism of the drug, paclitaxel should be given cautiously to patients with decreased liver function.&nbsp; Paclitaxel has been shown to cause a dose related elevation of liver enzymes.</p><p>When paclitaxel is given as a 24 hour infusion to patients with moderate to severe hepatic impairment, increased myelosuppression may be seen as compared to patients with mildly elevated liver function tests given 24 hour infusions.</p><p>Use in renal impairment</p><p>The effect of renal impairment on the pharmacokinetics of paclitaxel has not been established.</p><p>Use in the elderly</p><p>Of 2228 patients who received paclitaxel in eight clinical studies evaluating its safety and efficacy in the treatment of advanced ovarian cancer, breast carcinoma or NSCLC and 1570 patients who were randomised to receive paclitaxel in the adjuvant breast cancer study, 649 patients (17%) were 65 years or older, including 49 patients (1%) 75 years or older.&nbsp; In most studies, severe myelosuppression was more frequent in elderly patients; in some studies, severe neuropathy was more common in elderly patients.&nbsp; In two clinical studies in NSCLC, the elderly patients treated with paclitaxel had a higher incidence of cardiovascular events.&nbsp; Estimates of efficacy appeared similar in elderly patients and in younger patients; however, comparative efficacy cannot be determined with confidence due to the small number of elderly patients studied.&nbsp; In a study of first line treatment of ovarian cancer, elderly patients had a lower median survival than younger patients, but no other efficacy parameters favoured the younger group.</p><p>Paediatric use</p><p>The safety and effectiveness of paclitaxel in paediatric patients has not been established.. There have been reports of central nervous system (CNS) toxicity (rarely associated with death) in a clinical trial in paediatric patients in which paclitaxel&nbsp; was infused intravenously over 3 hours at doses ranging from 350 mg/m<sup>2</sup> to 420 mg/m<sup>2</sup>.&nbsp; The toxicity is most likely attributable to the high dose of the ethanol component of the paclitaxel vehicle given over a short infusion time.&nbsp; The use of concomitant antihistamines may intensify this effect.&nbsp; Although a direct effect of the paclitaxel itself cannot be discounted, the high doses used in this study (over twice the recommended adult dosage) must be considered in assessing the safety of paclitaxel for use in this population.</p><p>Effects on laboratory tests</p><p>No data available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cisplatin</p><p>The recommended regimen of paclitaxel administration for the first‑line chemotherapy of ovarian carcinoma is for paclitaxel to be given before cisplatin. When paclitaxel is given before cisplatin, the safety profile of paclitaxel is consistent with that reported for single‑agent use. Administration of cisplatin prior to paclitaxel treatment leads to greater myelosuppression than that seen when paclitaxel is given prior to cisplatin.&nbsp; In patients receiving cisplatin prior to paclitaxel, there is about a 33% decrease in paclitaxel clearance. Patients treated with paclitaxel and cisplatin may have an increased risk of renal failure as compared to cisplatin alone in gynecological cancers.</p><p>Doxorubicin</p><p>Sequence effects characterised by more profound neutropenic and stomatitis episodes have been observed with combination use of paclitaxel and doxorubicin when paclitaxel was administered before doxorubicin and using longer than recommended infusion times (paclitaxel administered over 24 hours; doxorubicin over 48 hours).&nbsp; Plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination and are given closer in time. Paclitaxel for initial treatment of metastatic breast cancer should be administered 24&nbsp;hours after doxorubicin (see Section&nbsp;4.2). However, data from a trial using bolus doxorubicin and 3 hour paclitaxel infusion found no sequence effects on the pattern of toxicity.</p><p>Cimetidine</p><p>Paclitaxel clearance is not affected by cimetidine premedication.</p><p>Drugs metabolised in the liver</p><p>The metabolism of paclitaxel is catalysed, in part, by cytochrome P450 isoenzymes CYP2C8 and 3A4.&nbsp; Clinical studies have demonstrated that CYP2C8 mediated metabolism of paclitaxel, to 6&alpha;-hydroxypaclitaxel, is the major metabolic pathway in humans. Concurrent administration of ketoconazole, a known potent inhibitor of CYP3A4, does not inhibit the elimination of paclitaxel in patients; thus, both medicinal products may be administered together without dosage adjustment. Further data on the potential of drug interactions between paclitaxel and CYP2C8 and 3A4 substrates/inhibitors are limited. Therefore, caution should be exercised when administering paclitaxel concomitantly with medicines known to inhibit (e.g., erythromycin, fluoxetine, gemfibrozil, deferasirox, trimethoprim) or induce (e.g., rifampicin, carbamazepine, phenytoin, phenobarbital, efavirenz, nevirapine, St John&rsquo;s wort) either CYP2C8 or 3A4.</p><p>In the clinical trial of paclitaxel in combination with trastuzumab (Herceptin), mean serum trough concentrations of trastuzumab were consistently elevated 1.5 fold as compared with serum concentrations of trastuzumab in combination with anthracycline plus cyclophosphamide (AC).</p><p>Arthralgia or myalgia adverse events of paclitaxel appear to be of a higher incidence in patients being treated concurrently with filgrastim (granulocyte colony stimulating factor; G-CSF).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects on fertility</p><p>Following treatment with intravenous paclitaxel at a dose of 1 mg/kg (6 mg/m<sup>2</sup>), rats showed decreased fertility and toxicity in unborn offspring.&nbsp; Paclitaxel administered intravenously to rabbits during organogenesis at a dose of 3 mg/kg (33 mg/m<sup>2</sup>) was toxic to both mother and foetus.</p><p><u>Infertility in Females and Males</u></p><p>Based on findings in animal studies, ANZATAX may impair fertility in females and males of reproductive potential.</p><p>&nbsp;</p><p>Paclitaxel is a cytotoxic agent that can produce spontaneous abortion, foetal loss and birth defects and may cause foetal harm when administered to a pregnant woman.&nbsp; Studies have shown paclitaxel to be toxic to embryos and foetuses in rabbits at an intravenous dose of 3 mg/kg (33 mg/m<sup>2</sup>) given during organogenesis.&nbsp; Paclitaxel is toxic to rat foetuses at a dose of 1 mg/kg (6 mg/m<sup>2</sup>) and produced low fertility and foetal toxicity in rats.&nbsp; Examination revealed that no gross external, soft tissue or skeletal alterations occurred.&nbsp; There are no studies in pregnant women.</p><p>Women of childbearing potential should have a pregnancy test prior to starting treatment with ANZATAX. These women should be strongly advised to use effective contraception throughout therapy and for at least six months after the last dose of ANZATAX.&nbsp; If paclitaxel is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard.</p><p><u>Females and Males of Reproductive Potential</u></p><p><em>Males</em></p><p>Based on findings in genetic toxicity and animal reproduction studies, males should be advised to use effective contraception in order to avoid fathering a child during treatment and for at least three months after the last dose of ANZATAX.</p><p><em>Females</em></p><p>Women of childbearing potential should be advised to use effective contraception in order to avoid becoming pregnant during treatment and for at least six months after the last dose of ANZATAX.</p><p>Use in lactation</p><p>It is not known whether paclitaxel is excreted in human milk.&nbsp; The evidence from many drugs would suggest that paclitaxel could be excreted in breast milk, though this is not known.&nbsp; Because infants receiving the drug could experience serious adverse effects, breastfeeding should be discontinued while the mother is undergoing treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The effects of this medicine on a person&#39;s ability to drive and use machines were not assessed as part of its registration. Patients should refrain from driving or using machines until they know that paclitaxel does not negatively affect these abilities. It should be noted that paclitaxel contains ethanol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following is based on the experience of 812 patients treated in Phase II and III clinical trials.&nbsp; The frequency and severity of adverse effects are generally similar between patients receiving paclitaxel for the treatment of ovarian, breast or lung cancer.&nbsp; None of the observed effects were clearly influenced by age.&nbsp; Unless stated otherwise, percent figures, where given, are based on observed incidence when using the recommended dosing regime.&nbsp; If other regimes are used, the incidence of reaction may be higher.</p><p>Safety of the paclitaxel/platinum combination has been investigated in a large randomised trial in ovarian cancer and in two Phase III trials in NSCLC.&nbsp; Unless otherwise mentioned, the combination of paclitaxel with platinum agents did not result in any clinically relevant changes to the safety profile of single agent paclitaxel.</p><p>Adverse effects reported were those occurring during or following the first course of therapy, and have, where possible, been grouped by frequency according to the following criteria.</p><p><em>Very common:</em>&nbsp; &sup3;1/10</p><p><em>Common:</em>&nbsp; &sup3;1/100 and &lt;1/10</p><p><em>Uncommon:</em>&nbsp; &sup3;1/1000 and &lt;1/100</p><p><em>Rare:</em>&nbsp; &sup3;1/10000 and &lt;1/1000</p><p><em>Very rare:</em>&nbsp; &lt;1/10000</p><p><strong>Cardiovascular</strong></p><p><em>Very common:</em>&nbsp; Hypotension.</p><p><em>Common:</em>&nbsp; Bradycardia; ECG abnormalities (non-specific repolarisation and sinus tachycardia).</p><p><em>Uncommon:</em>&nbsp; ECG abnormalities (premature beats), cardiomyopathy.</p><p><em>Rare:</em>&nbsp; Myocardial infarction; congestive heart failure (typically in patients who have received other chemotherapy, notably anthracyclines).</p><p>Six severe cardiovascular events possibly related to paclitaxel administration occurred including asymptomatic ventricular tachycardia, tachycardia with bigeminy, atrioventricular block (2 patients), and syncopal episodes (2 patients - in one associated with severe hypotension and coronary stenosis resulting in death).&nbsp; Severe hypotensive reactions have been associated with serious hypersensitivity reactions and have required intervention. Cardiac failure and sinus bradycardia have also been observed.</p><p><strong>Haematological</strong></p><p><em>Very common:</em>&nbsp; Myelosuppression, thrombocytopenia, leucopoenia, fever, bleeding, anaemia; neutropenia (Overall, 52% of the patients experienced severe Grade IV neutropenia and 56% had Grade III/IV severe neutropenia on their first course.&nbsp; Neutrophil nadirs occurred at a median of 11 days after paclitaxel administration).</p><p><em>Common:</em>&nbsp; Febrile neutropenia (associated with an infectious episode, including UTI and URTI).</p><p><em>Rare:</em>&nbsp; Five septic episodes, which were associated with severe neutropenia attributable to paclitaxel administration had a fatal outcome.</p><p>Patients who have received prior radiation or cisplatin therapy exhibit more frequent myelosuppression, which is generally of greater severity (see section 4.4 Special warnings and precautions for use and section 4.5 Interactions with other medicines and other forms of interactions).</p><p><strong>Hepatobiliary</strong></p><p><em>Very common:</em>&nbsp; Elevated alkaline phosphatase; elevated AST; elevated ALT.</p><p><em>Common:</em>&nbsp; Elevated bilirubin.</p><p><em>Rare:</em>&nbsp; Hepatic necrosis (leading to death); hepatic encephalopathy (leading to death).</p><p><strong>Hypersensitivity</strong></p><p><em>Very common:</em>&nbsp; Flushing; rash.</p><p><em>Common:</em>&nbsp; Dyspnoea; hypotension; chest pains; tachycardia.</p><p><em>Uncommon:</em> &nbsp;Significant hypersensitivity reactions requiring therapy (eg. Hypotension, angioneurotic oedema, bronchospasm, respiratory distress, generalised urticaria, oedema, back pains, pain in extremities, chills, diaphoresis).</p><p><strong>Infections and Infestation</strong></p><p><em>Very Common:</em> &nbsp;Infection</p><p><em>Uncommon:</em> &nbsp;Septic shock</p><p><strong>Gastrointestinal</strong></p><p><em>Very common:</em>&nbsp; Nausea; vomiting; diarrhoea; mucositis (These manifestations were usually mild to moderate at the recommended dose.)</p><p><em>Rare:</em>&nbsp; Bowel perforation (There have been several cases of bowel perforation associated with patients receiving paclitaxel.&nbsp; Patients receiving paclitaxel who complain of abdominal pain with other signs and symptoms, should have bowel perforation excluded.)</p><p>Neutropenic enterocolitis has been reported.</p><p><strong>Vascular Disorders</strong></p><p><em>Very common:</em>&nbsp; Hypotension</p><p><em>Uncommon:</em> &nbsp;Hypertension, thrombosis, thrombophlebitis</p><p><strong>Musculoskeletal</strong></p><p><em>Very common:</em>&nbsp; Arthralgia; myalgia (The symptoms were usually transient occurring two to three days after paclitaxel administration and resolving within a few days.)</p><p><strong>Neurological</strong></p><p><em>Very common:</em>&nbsp; Peripheral neuropathy (Peripheral neuropathy occurs and is dose dependent with 60% of patients experiencing Grade I toxicity, 10% Grade II and 2% Grade III at the recommended doses.&nbsp; Neuropathy was present in 87% of patients at higher doses.&nbsp; Severity of symptoms also increased with dose; 4% of patients experienced severe symptoms at the recommended dose versus 10% at higher doses.&nbsp; Neurologic symptoms may occur following the first course and symptoms may worsen with increasing exposure to paclitaxel.&nbsp; Peripheral neuropathy was the cause of paclitaxel discontinuation in 2% of patients.&nbsp; Sensory symptoms have usually improved or resolved within several months of paclitaxel discontinuation).</p><p><em>Rare:</em>&nbsp; Optic nerve and/or visual disturbances (scintillating scotomata) particularly in patients who have received higher doses than recommended; these effects generally have been reversible; motor neuropathy with resultant minor distal weakness and autonomic neuropathy resulting in paralytic ileus and orthostatic hypotension.</p><p><strong>Skin and Appendages</strong></p><p><em>Very common:</em>&nbsp; Alopecia.</p><p><em>Rare:</em>&nbsp; Nail and skin changes (mild and transient); radiation-recall dermatitis; recall dermatitis.</p><p><em>Local:</em>&nbsp; Phlebitis following intravenous administration has been reported.&nbsp; Extravasation leading to oedema, pain, erythema and induration has been reported. On occasions, extravasation can lead to cellulitis.&nbsp; Skin discolouration may also occur.</p><p><strong>General Disorders and Administration Site Conditions</strong></p><p><em>Common:</em>&nbsp; Injection site reactions (including localised oedema, pain, erythema, induration, on occasion extravasation can result in cellulitis.</p><p>Injection site reactions, including reactions secondary to extravasation, were usually mild and consisted of erythema, tenderness, skin discolouration, or swelling at the injection site.&nbsp; These reactions have been observed more frequently with the 24 hour infusion than with the 3 hour infusion. Recurrence of skin reactions at a site of previous extravasation following administration of paclitaxel at a different site, i.e., &lsquo;recall&rsquo;, has been reported rarely.</p><p>Rare reports of more severe events such as phlebitis, cellulitis, induration, skin exfoliation, necrosis and fibrosis have been received as part of the continuing surveillance of paclitaxel safety.&nbsp; In some cases the onset of the injection site reaction either occurred during a prolonged infusion or was delayed by a week to ten days.</p><p>A specific treatment for extravasation reactions is unknown at this time.&nbsp; Given the possibility of extravasation, it is advisable to closely monitor the infusion site for possible infiltration during drug administration.</p><p>Radiation pneumonitis has been reported in patients receiving concurrent radiotherapy.</p><p>Post-marketing experience</p><p>The following additional adverse reactions have been identified during post approval use of paclitaxel.&nbsp; Because the reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a casual relationship to drug exposure.</p><p><u>Infections and Infestations:</u></p><p>Pneumonia, sepsis.</p><p><u>Cardiac Disorders:</u></p><p>Atrial fibrillations, supraventricular tachycardia, reduction of left ventricle ejection fraction, ventricular failure.</p><p><u>Haemotological Disorders:</u></p><p>Acute myeloid leukaemia, myelodysplastic syndrome.</p><p><u>Immune System Disorders:</u></p><p>Anaphylactic reactions (with fatal outcome), anaphylactic shock, cross-hypersensitivity</p><p>between ANZATAX and other taxanes has been reported.</p><p><u>Metabolism and Nutritional Disorders:</u></p><p>Anorexia, tumour lysis syndrome</p><p><u>Psychiatric Disorders:</u></p><p>Confusion state.</p><p><u>Vascular Disorders:</u></p><p>Shock.</p><p><u>Respiratory, Thoracic and Mediastinal Disorders:</u></p><p>Dyspnoea, pleural effusion, respiratory failure, interstitial pneumonia, lung fibrosis, pulmonary embolism, cough.</p><p><u>Gastrointestinal Disorders:</u></p><p>Bowel obstruction, bowel perforation, ischemic colitis, pancreatitis, mesenteric thrombosis, pseudomembranous colitis, oesophagitis, constipation, ascites.</p><p><u>Neurological disorders:</u></p><p>Autonomic neuropathy (resulting in paralytic ileus and orthostatic hypotension), grand mal seizures, convulsions, encephalopathy, dizziness, headache, ataxia, parasthesia, hyperesthesia.</p><p><u>Eye Disorders:</u></p><p>Photopsia, visual floaters, cystoid macular oedema, macular oedema.</p><p><u>Ear and Labyrinth Disorders:</u></p><p>Hearing loss, tinnitus, vertigo, ototoxicity.</p><p><u>Skin and Subcutaneous Tissue Disorders:</u></p><p>Stevens-Johnson syndrome, epidermal necrolysis, erythema multiforme, exfoliative dermatitis, urticaria, onycholysis (patients on therapy should wear sun protection on hands and feet), pruritus, rash, erythema, phlebitis, cellulitis, skin exfoliation, necrosis, fibrosis, palmar-plantar erythrodysesthesia syndrome.</p><p><u>Musculoskeletal and Connective Tissue Disorders:</u></p><p>Systemic lupus erythematosus, scleroderma</p><p><u>Investigations:</u></p><p>Increase in blood creatinine.</p><p><u>General Disorders and Administration Site Conditions:</u></p><p>Asthenia, malaise, pyrexia, dehydration, oedema.</p><p><strong><u>Reporting of adverse reactions</u></strong></p><p>Reporting suspected adverse reactions after <u>marketing</u> authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions <u>according to their local requirements. </u></p><p><strong>To Report side effects</strong></p><ul><li>Saudi Arabia</li></ul><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre ( NPC )</p><ul><li>&nbsp;</li></ul><p>&middot;&nbsp;&nbsp; Call NPC at +966-11-2038222, Ext 2317-2356-2340</p><p>&middot;&nbsp;&nbsp; Call center : 19999</p><p>&middot;&nbsp;&nbsp; Fax: +966 11 205 7662</p><p>&middot;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><ul><li>Website :https://ade.sfda.gov.sa/&nbsp;&nbsp;</li></ul><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC States</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>At present there is no specific treatment for paclitaxel overdosage. In case of overdose, the patient should be closely monitored. Probable consequences of an overdose are mucositis, severe bone marrow suppression and peripheral neurotoxicity and treatment should be supportive.</p><p>Overdoses in paediatric patients may be associated with acute ethanol toxicity. Treatment is symptomatic and supportive.</p><p>For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mechanism of action</p><p>Paclitaxel is an antimicrotubule antineoplastic agent.&nbsp; It promotes microtubule assembly by enhancing the polymerisation of tubulin, the protein subunit of spindle microtubules, even in the absence of the mediators normally required for microtubule assembly (e.g., guanosine triphosphate [GTP]), thereby inducing the formation of stable, nonfunctional microtubules.&nbsp; While the precise mechanism of action of the drug is not completely known, paclitaxel disrupts the dynamic equilibrium within the microtubule system and blocks cells in the late G2 phase and M phase of the cell cycle, inhibiting cell replication and impairing function of nervous tissue.</p><p>Clinical trials</p><p>No data available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Distribution</p><p>After paclitaxel is administered intravenously, its plasma concentration declines biphasically.</p><p>The first phase shows rapid decline representing distribution of paclitaxel to the peripheral compartment and elimination.&nbsp; This initial phase is followed by a relatively slow elimination of paclitaxel from the peripheral compartment.</p><p>Mean steady state volume of distribution following single dose infusion of 135 and 175 mg/m<sup>2</sup> has ranged from 198 to 688 L/m<sup>2</sup>, indicating extensive extravascular distribution and/or tissue binding.</p><p>The serum protein binding of paclitaxel is 89% following a three hour infusion of 175 mg/m<sup>2</sup> paclitaxel.</p><p>Metabolism</p><p>The liver is thought to be the primary site of metabolism for paclitaxel.</p><p>Excretion</p><p>In patients treated with doses of 135 and 175 mg/m<sup>2</sup> given as 3 and 24 hour infusions, mean terminal half-life has ranged from 3.0 to 52.7 hours and total body clearance has ranged from 11.6 to 24.0 L/hour/m<sup>2</sup>.</p><p>Following three hour infusions of 175 mg/m<sup>2</sup>, mean terminal half-life was estimated to be 9.9 hours; mean total body clearance was 12.4 L/hour/m<sup>2</sup>.</p><p>The mean cumulative urinary recovery of unchanged paclitaxel has been reported as 1.8 to 12.6% of the dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Genotoxicity</p><p><em>In vitro</em> studies (chromosome abnormalities in human lymphocytes) and <em>in vivo</em> (micronucleus test using mice) mammalian test systems have shown paclitaxel to be mutagenic.&nbsp; When testing using the Ames test or the CHO/HGPRT gene mutation assay, paclitaxel did not induce mutagenicity.</p><p>Carcinogenicity</p><p>No studies have examined the carcinogenic potential of paclitaxel, however, drugs similar to paclitaxel are carcinogens.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Anhydrous Citric Acid</p><p>Castor Oil</p><p>Ethanol</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Do not use Anzatax after the expiry date which is stated on the Vial label after EXP:. The expiry date refers to the last day of that month.
 The shelf life is 24 months.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below <strong>25&ordm;C</strong></p><p><strong>Keep out of the sight and reach of children.</strong></p><p><strong>Dilution</strong></p><p>Anzatax Injection Concentrate MUST BE DILUTED PRIOR TO INTRAVENOUS INFUSION.&nbsp; It should be diluted in 5% glucose or 0.9% sodium chloride intravenous infusion.</p><p>Dilution should be made to a final concentration of 0.3 to 1.2 mg/mL.</p><p>After the final dilution of Anzatax Injection Concentrate, the bottle should be swirled gently to disperse the paclitaxel.&nbsp; DO NOT SHAKE.</p><p>Avoid contact of paclitaxel solutions with plasticised polyvinyl chloride (PVC) equipment,<strong> </strong>infusion lines or devices used when preparing infusion solutions.<strong>&nbsp; </strong>Prepare and store diluted paclitaxel solutions in glass bottles or non-PVC infusion bags.&nbsp; These precautions are to avoid leaching of the plasticiser DEHP (di-[2-ethylhexyl] phthalate) from PVC infusion bags or sets.&nbsp; Paclitaxel solutions should be administered through polyethylene lined administration sets (e.g. Gemini 20 giving set), using an IMED<sup>&reg;</sup> pump.</p><p>Although solutions of paclitaxel for infusion prepared as outlined above are chemically stable for 3 days at room temperature (25&deg;C) and 14 days at 2&deg;C to 8&deg;C, it is recommended that the solution for infusion should be administered immediately after preparation as it does not contain an antimicrobial agent.&nbsp; The infusion should be completed within 24 hours of preparation of the solution and any residue discarded, according to the guidelines for the disposal of cytotoxic drugs (see 6.6 Special precautions for disposal and other handling).&nbsp; Use in one patient on one occasion only.</p><p>Compounding centres which:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are licensed by the TGA to reconstitute and/or further dilute cytotoxic products; and</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have validated aseptic procedure and regular monitoring of aseptic technique may apply the following shelf lives when stored under the specified conditions:</p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Diluent</p></td><td colspan="2" style="vertical-align:top"><p>Stored Below 25&deg;C</p></td><td colspan="2" style="vertical-align:top"><p>Stored at 2&deg;C to 8&deg;C (Refrigerate.&nbsp; Do not freeze)</p></td></tr><tr><td style="vertical-align:top"><p>Non-PVC Infusion Bag</p></td><td style="vertical-align:top"><p>Glass Bottle</p></td><td style="vertical-align:top"><p>Non-PVC Infusion Bag</p></td><td style="vertical-align:top"><p>Glass Bottle</p></td></tr><tr><td style="vertical-align:top"><p>0.9% Sodium Chloride for Intravenous Infusion</p></td><td style="vertical-align:top"><p>7 days</p></td><td style="vertical-align:top"><p>3 days</p></td><td style="vertical-align:top"><p>28 days</p></td><td style="vertical-align:top"><p>14 days</p></td></tr><tr><td style="vertical-align:top"><p>5% Glucose for Intravenous Infusion</p></td><td style="vertical-align:top"><p>3 days</p></td><td style="vertical-align:top"><p>3 days</p></td><td style="vertical-align:top"><p>14 days</p></td><td style="vertical-align:top"><p>14 days</p></td></tr></tbody></table><p>&nbsp;</p><p>Solutions prepared this way have been shown to be chemically stable for these periods.&nbsp; Administration should be completed within 24 hours of the start of the infusion and any residue discarded according to the guidelines for the disposal of cytotoxic drugs.&nbsp; Do not use paclitaxel if any precipitation forms or if the diluted solution appears cloudy.</p><p><strong>Filtration</strong></p><p>A microporous membrane of 0.22 microns or less in size is recommended as the in-line filter for all infusions of paclitaxel.&nbsp; The IMED 0.2 micron add on filter set composed of polysulfone and the IVEX&trade; II 0.2 micron filter composed of cellulose have both been found to be suitable for Anzatax Injection Concentrate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Anzatax Injection Concentrate is a sterile solution containing 6 mg/mL paclitaxel, 2 mg/mL Anhydrous Citric Acid, 527 mg/mL Castor Oil and Ethanol.&nbsp; It is a clear to pale yellow solution, free of visible particles.</p><p>Anzatax Injection Concentrate has a pH of 6 to 7.&nbsp; Paclitaxel is extremely hydrophobic, and is therefore formulated in castor oil and ethanol.</p><p>Anzatax Injection Concentrate is available in single packs in the following presentations:</p><p>Anzatax Injection Concentrate 30 mg/5 mL Onco- tain&nbsp; vials</p><p>Anzatax Injection Concentrate 150 mg/25 mL Onco-tain&nbsp; vials</p><p>&nbsp; Onco-tain vials are sheathed with a protective clear plastic sleeve and a base cap as an optional format based on marketing requirements. The shrink-wrapped (Onco-Tain) vials are generally preferred by practitioners for the following reasons:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;There is a reduced risk of operator contamination</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The shrink-wrapping provides added resistance to breakage</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased product containment upon breakage</p><p>These features provide an additional level of safety for medical personnel and patients during the preparation and handling of the product, which is particularly important for oncology products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The published guidelines related to procedures for the proper handling and disposal of cytotoxic drugs should be followed.</p><p>Care must be taken whenever handling cyostatic products.&nbsp; Always take steps to prevent exposure.&nbsp; This included appropriate equipment, such as wearing gloves and washing hands with soap and water after handling such products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER
Pfizer Australia Pty Ltd, Level 17, 151 Clarence street, Sydney, NSW 2000, Australia

MANUFACUTRED BY
HOSPIRA AUSTRALIA, 
MULGRAVE, 
Australia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Septmeber 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>